G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

The world of medicine has taken a significant leap forward with the first AI-generated drug entering clinical trials. This breakthrough has the potential to revolutionize drug discovery, transforming ...

The most familiar artificial intelligence (AI) applications include text generation, facial recognition, and autonomous driving. But there are other AI applications that deserve their share of ...

Dr. Khaled Elokely specializes in the integration of computational and medicinal chemistry for innovative drug design and development at the University of Wyoming. With a background in pharmaceutical ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

Researchers from David Baker's lab (University of Washington) have designed this antibody from scratch to neutralize a deadly toxin from C. difficile. [Ian Haydon] “Life could not exist without ...

Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with ...

Ola Engkvist is the Executive Director and Head of Molecular AI in Discovery Sciences within R&D at AstraZeneca (headquartered in Cambridge, UK). His team harnesses advanced computational technologies ...